Hesperos researchers, in collaboration with the University of Central Florida (UCF), have developed a multi-organ, microphysiological acute opioid overdose and recovery (AOOR) model designed to help address the opioid crisis. This human cell-based platform replicates the physiological aspects of an overdose and recovery, allowing researchers to evaluate recovery agents like naloxone for both efficacy and off-target toxicity. The AOOR model could serve as a platform for testing other recovery agents, potentially advancing safer and more effective treatments for opioid overdose. We are proud of our team for their incredible work and dedication to finding solutions that address the opioid crisis. We also want to thank The National Institutes of Health HEAL initiative for their support on this study. Read the study and press release here: https://buff.ly/3C3M5F8 #Publication #Overdose #OrganOnAChip #HumanOnAChip #MPS #HEAL #NIH #Research #Hesperos
关于我们
Hesperos, Inc. is accelerating drug discovery by providing safety and efficacy testing of chemicals and novel therapeutics for the pharmaceutical, cosmetic, and food industries using its patented, Human-on-a-Chip platform. Bringing together biologists, surface chemists, and engineers, our team is producing some of the world's most advanced organs-on-a-chip platforms. From gene expression to electrophysiology, we recreate key components of organs in an interconnected, functional system. Chemically patterned microchips enable real-time, non-invasive monitoring of organ function where we use sophisticated measurement techniques to detect minute changes. This breakthrough technology enables unprecedented visibility into specific disease states and how the human body will respond to treatment - something that previously required costly animal testing and human trials to determine. The functional, interconnected, human in vitro platform, provides preclinical insight into the efficacy and toxicity of novel therapeutics. Ultimately, Hesperos’ Human-on-a-Chip is reducing the need for animal testing in drug discovery while enabling research into rare diseases previously considered untreatable.
- 网站
-
http://www.hesperosinc.com/
Hesperos Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Orlando，Florida
- 类型
- 私人持股
- 创立
- 2015
- 领域
- In Vitro Biology、ADME Systems、Nanotechnology、organ-on-a-chip和organs-on-chips
地点
-
主要
获取路线
3259 Progress Dr
US，Florida，Orlando，32826
Hesperos Inc.员工
动态
-
Hesperos Chief Scientist, J. Hickman, is speaking this week at "Advances in Developing Medical Countermeasures Against Opioids and Drug-Induced Respiratory Depression," hosted by the National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA). He will cover how we use #HumanOnAChip models to reproduce opiate overdose and recovery to better understand efficacy and off-target effects of potential therapeutics. Learn more about the meeting and other speakers here: https://buff.ly/4izkDzp #NIH #NIAID #BARDA #Overdose #Opioid #OrganOnAChip #Biotech
-
-
Join us for The 3Rs Collaborative (3RsC)'s Oncology MPS workshop tomorrow, Dec. 4, 10 am EST! Hesperos will be 1 of 9 companies presenting oncology models. This is the last of a series of webinars established by the 3RsC in collaboration with IQ-MPS. Register to watch free here: https://buff.ly/498DnBC #3Rs #3RsCollaborative #MPS #NAMS #organonachip
-
-
Hesperos Chief Scientist J. Hickman is virtually presenting today at PAGICLE Ltd's World Pharma 2024. His talk, “Human-on-a-chip systems as pre-clinical models for neurological diseases and disorders," will be at 11:10 am EST. World Pharma 2024 is a virtual gathering for the health industry professionals worldwide. Directors, scientists, professors, and research scholars are invited to share their research and discuss emerging technological trends in the pharmaceutical industry. Learn more about World Pharma 2024 and Dr. Hickman's presentation at https://buff.ly/4fg6sNF #WorldPharma2024 #NAMs #Humanonachip #Neuroscience
-
-
We look forward to being at BioFlorida, Inc.'s Florida Innovation Conference next week! Stop by booth #27 to learn more about our latest progress and catch Dr. Hickman during the panel discussion Track A: Growth Company Spotlights | Biotechnology and Pharmaceuticals Tuesday at 10:45am. Learn more about the Florida Innovation Conference at https://buff.ly/3YStQeA #biotech #Humanonachip #Organonachip #bioflorida #BioFL2024
-
-
Hesperos scientist Kaveena Autar is presenting this week at Gerontological Society of America (GSA)'s 2024 Annual Scientific Meeting in Seattle. She is presenting Poster #270, “Investigating Drug-Induced Dementia in a CNS MPS Assessing Deficits in LTP From Anticholinergic Cognitive Burden," on Nov. 15 2:00-3:15 PM PST. Be sure to stop by to meet her and learn more! GSA 2024 is a premier annual scientific meeting for cutting-edge scholarship, research, and networking relating to the fields of aging and gerontology. Learn more about GSA 2024 and Dr. Autar's poster presentation here: https://buff.ly/4fCS426 #GSA2024 #Neuroscience #DementiaResearch
-
-
Hesperos Chief Scientist J Hickman is presenting at Oxford Global's Discovery US 2024 in Boston today! His talk titled "Organ-On-Chip & MPS Systems for Neurodegenerative Diseases” is during Track 2 (Novel Models for ADME-TOX Research & Disease Modeling) at 3:05pm. Discovery US 2024 brings together leading biopharma experts dedicated to sharing insights, and tackling the toughest challenges in drug development. We hope to see you there! https://buff.ly/3YUOyKK #NAMS #HumanonaChip #OrganonaChip #OxfordGlobal #drugdiscovery
-
-
Congratulations to the Hesperos and University of Central Florida research teams on their new publication in ACS Biomaterials Science and Engineering! This study presents a human induced pluripotent stem cell (iPSC)-derived model of peripheral myelination, enabling investigations into various peripheral nervous system diseases and potential treatments, such as Charcot-Marie-Tooth disorder, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy (CIDP). Read the full study and press release here: https://buff.ly/40iGjt3 #OrganOnAChip #RareDisease #Research #HumanOnAChip #Publication #ACSBSE
-
-
Hesperos is pleased to announce the appointment of Lawrence Florin as Chief Executive Officer. Mr. Florin is a recognized leader in life sciences with more than 20 years' experience in global leadership roles, founding and growing SMOs, CROs, and clinical technology companies. His deep expertise in clinical research and his passion for innovation align seamlessly with our mission to accelerate the development of safer, more effective therapeutics. Learn more and read the full press release here: https://buff.ly/3BVrvq8 #HumanOnAChip #LifeSciences #Leadership #Biotech #PressRelease
-
-
Super excited to be representing Hesperos Inc. today at SFN 2024! Stop by Poster C18 this morning to learn more about our conduction velocity platform and Human-on-a-Chip technologies. #SFN2024